Medivir is a drug discovery and development company focusing on transformative cancer drugs. Our research and development are based on our extensive expertise in protease inhibitor design and nucleoside/nucleotide science.Our research >
Medivir focuses on cancers of high unmet medical need to provide benefit to patients who so far have had few treatment options.Our projects >
Medivir leverages collaborations with academic and industrial partners in order to bring specialty knowledge, experience and other capabilities to our projects in various phases.Partnership >
Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignanciesRead more
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2018Read more
New data from the MIV-711 phase II program will be presented at the ACR Annual Meeting on October 21Read more
Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.